Open, Single-center, Phase II clinical study for Sintilimab (IBI308) in the maintenance therapy after second-line chemoradiotherapy for local and/or regional recurrent esophageal squamous cell cancer patients
Latest Information Update: 04 Feb 2020
At a glance
- Drugs Sintilimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 04 Feb 2020 New trial record